BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260915
DTEND;VALUE=DATE:20260918
DTSTAMP:20260613T205947
CREATED:20260515T123626Z
LAST-MODIFIED:20260515T123626Z
UID:43540-1789430400-1789689599@www.pharmajournalist.com
SUMMARY:COPD Drug Development Summit
DESCRIPTION:The First Industry‑Led Meeting Dedicated to Advancing Next‑Generation COPD Therapeutics \nThe COPD Drug Development Summit is the first and only industry‑driven forum designed to accelerate meaningful innovation in chronic obstructive pulmonary disease. \nWith the approval of the first biologic therapy marking a historic turning point\, COPD R&D is entering a new era\, one defined by deeper biological understanding\, more precise patient segmentation\, and a renewed push toward disease‑modifying treatments. \nThis summit convenes leading scientists\, clinicians\, regulatory experts\, and biotech innovators to address the scientific and operational barriers that have long constrained progress. \nOver three days\, attendees will explore the most urgent and promising areas shaping the future of COPD therapeutics. \nCore themes include novel target discovery\, translational alignment\, and smarter clinical trial design that reflects the heterogeneity of COPD endotypes. \nThe program also examines the limitations of traditional endpoints such as exacerbations and FEV₁\, highlighting next‑generation measures\, including imaging‑based progression tools\, AI‑enabled assessment\, and biomarkers capable of capturing early disease activity and therapeutic impact. \nWith 65+ industry leaders and 16+ expert speakers from organisations including Johnson & Johnson\, Sanofi\, GSK\, AstraZeneca\, Merck\, Generate Biomedicines\, and Ethris\, the summit offers a uniquely concentrated environment for scientific exchange and partnership building. \nParticipants will engage in 7+ hours of structured networking\, panel discussions\, and case‑study‑driven sessions that illuminate both the opportunities and the remaining challenges in COPD drug development. \nDesigned for discovery scientists\, translational researchers\, clinical developers\, regulatory strategists\, and biotech executives\, this event provides a rare chance to shape the next chapter of COPD innovation. \nAs the field moves toward more personalised\, mechanism‑driven approaches\, the COPD Drug Development Summit serves as a critical platform for aligning science\, strategy\, and regulatory confidence to deliver better outcomes for millions of patients worldwide. \nRegister now: https://ter.li/kvevwxqk
URL:https://www.pharmajournalist.com/event/copd-drug-development-summit/
LOCATION:Homewood Suites by Hilton Boston Seaport District\, 670 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260915
DTEND;VALUE=DATE:20260918
DTSTAMP:20260613T205947
CREATED:20260522T112301Z
LAST-MODIFIED:20260522T112301Z
UID:43581-1789430400-1789689599@www.pharmajournalist.com
SUMMARY:11th CAR-TCR Summit
DESCRIPTION:All eyes are on the next wave of CAR and TCR innovation. Success is no longer defined by clinical wins alone\, but by smarter biological design\, delivery strategies and manufacturing breakthroughs to lower COGs\, expand patient access and secure commercial viability. \nWith this\, the 11th CAR-TCR Summit is making its hotly anticipated return to Boston\, September 15-17. \nView the agenda here. \nCrafted in collaboration with industry veterans and spanning four tracks across the entire development life cycle\, the program offers a clear\, strategic view of the next era of cell therapy. Expect first hand insight into cutting-edge in vivo and next generation CAR and TCR innovations\, hear unpublished clinical data across emerging indications\, and learn from real world automated manufacturing case studies shaping commercial readiness. \nBeyond the science\, you’ll gain direct access to investors to align on where capital and strategic partnerships are moving next\, complemented by high-value networking with C-suite executives and academic KOLs to safegaurd every stage of your cell therapy development pipeline. \nIf you’re committed to driving the innovation and commercial readiness needed to make CAR-T therapies safer\, more effective\, scalable\, and accessible to the patients who need them most\, then this is the meeting for you. \nDownload your copy of the agenda.
URL:https://www.pharmajournalist.com/event/11th-car-tcr-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260915
DTEND;VALUE=DATE:20260918
DTSTAMP:20260613T205947
CREATED:20260529T112818Z
LAST-MODIFIED:20260529T112818Z
UID:43646-1789430400-1789689599@www.pharmajournalist.com
SUMMARY:Measuring Patient Engagement Summit Europe
DESCRIPTION:The Measuring Patient Engagement Summit Europe is the leading industry forum dedicated to supporting biopharma in quantifying and demonstrating the true impact of patient engagement. As regulatory expectations rise and internal stakeholders demand a clearer return on investment\, the need for robust\, evidence-based frameworks has never been greater. This three-day summit brings together over 70 senior leaders across patient engagement\, advocacy\, insights\, experience\, and medical affairs to address one of the industry’s most pressing challenges – moving from activity-based reporting to measurable impact and defensible KPIs. \nDesigned to bridge the gap between strategy and proof\, the event focuses on establishing credible\, comparable\, and actionable metrics that demonstrate how patient engagement influences decision-making across the product lifecycle. Attendees will gain practical insights into how patient input drives improvements in protocol design\, accelerates clinical trial recruitment\, supports regulatory alignment\, and strengthens market access outcomes. \nThrough a combination of real-world case studies\, expert-led discussions\, and collaborative sessions\, the summit offers a unique opportunity to benchmark approaches\, co-develop frameworks\, and create a shared language of value recognised by regulators\, payers\, and patients alike. By equipping participants with proven methodologies and peer-tested tools\, the event empowers organisations to embed patient engagement as a strategic\, data-driven driver of innovation – ensuring its impact is both defensible and impossible to ignore. \nAgenda Highlights Include: \n\nMoving beyond activity-based KPIs to define and measure meaningful patient engagement impact\nDemonstrating measurable outcomes across clinical trial design\, recruitment\, and retention\nQuantifying the influence of patient insights on regulatory\, payer\, and market access decisions\nDeveloping credible and standardised frameworks to benchmark engagement success\nTranslating patient experience data into tangible clinical and commercial value\nAligning patient engagement strategies with ESG and broader organisational priorities\nBuilding a common language of value recognised across industry stakeholders\n\nThis summit provides a critical platform for advancing the measurement of patient engagement\, enabling organisations to shift from intention to evidence and truly demonstrate the value of patient-centric approaches. \nGet your copy of the agenda now to learn more: https://ter.li/fy580o27.
URL:https://www.pharmajournalist.com/event/measuring-patient-engagement-summit-europe/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260923
DTEND;VALUE=DATE:20260925
DTSTAMP:20260613T205947
CREATED:20260528T105430Z
LAST-MODIFIED:20260528T105430Z
UID:43620-1790121600-1790294399@www.pharmajournalist.com
SUMMARY:5th Lipid Nanoparticles Development Summit Europe
DESCRIPTION:The 5th Lipid Nanoparticles Development Summit Europe returns to Berlin\, 23rd – 24th  September 2026\, as the leading meeting for advancing LNP-enabled gene therapy delivery. Bringing together experts from BioNTech\, AstraZeneca\, Johnson & Johnson\, Sanofi and AbbVie\, the summit covers end-to-end LNP development\, from formulation through to analytics\, CMC and scalable manufacturing. Attendees will explore solutions to overcome liver tropism\, enable extrahepatic delivery and engineer next-generation nanoparticle systems across mRNA\, DNA and gene editing therapies. With interactive discussions and real-world case studies\, this event delivers actionable insights to accelerate safe\, targeted and clinically viable delivery platforms. \nTo learn more and register online\, please visit: https://ter.li/mft1fbw0
URL:https://www.pharmajournalist.com/event/5th-lipid-nanoparticles-development-summit-europe/
LOCATION:Dorint Kurfürstendamm Berlin\, Augsburger Strasse 41\, Berlin\, 10789\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260928
DTEND;VALUE=DATE:20261001
DTSTAMP:20260613T205947
CREATED:20260528T115319Z
LAST-MODIFIED:20260528T115319Z
UID:43639-1790553600-1790812799@www.pharmajournalist.com
SUMMARY:7th Genome Editing Therapeutics Summit
DESCRIPTION:The FDA has shown its’ hand. The Plausible Mechanism Framework and new NGS safety guidance signal one thing clearly: regulators want genome editing therapies to reach patients. Biopharma is also pushing back with a surge of novel genome editing assets deployed in the last 2 years\, targeting rare and prevalent diseases with scarce treatment options. \n \nBut intent and support alone won’t get these therapies to patients. Developmental\, manufacturing\, and regulatory challenges still stand between the lab and the patients waiting. \nThat’s why the 7th Genome Editing Therapeutics Summit is returning to Boston this September\, as the only industry-focused meeting dedicated to applying breakthrough genome editing tools directly to the therapeutic setting. \nJoin R&D\, preclinical\, translational\, regulatory\, and c-suite leaders to answer one question: how do we maximize the application of genome editing therapies to patients who need them most? \nDon’t miss out on insights from AbbVie\, Bristol Myers Squibb\, Intellia Therapeutics\, Beam Therapeutics\, Sanofi\, and many more on how genome editing can move from a promising therapy to an essential one for patients facing the most genetically complex diseases.   \nWhat’s New in 2026? \nIn 2026\, companies are doubling down on translating cutting-edge genome editing technologies into clinically viable therapies. With the FDA’s new mechanism pathway reshaping strategy\, the decisions made now will determine which assets reach patients. \nAt this year’s summit you will: \n\nDelve into extrahepatic delivery strategies to widen your technology across multiple disease indications\n\n\nLearn from clinical companies building robust IND packages to fast-track development\n\n\nEvaluate immunogenicity and off-targeting case studies to sharpen your therapy’s safety profile\n\nExplore the Brand-New Agenda to Discover: \n\n3 days of content to find the sessions your program needs most\n\n\n50:50 clinical & preclinical speakers to find genome editing talks relevant to your development stage\n\n\n80% Directors\, VPs & C-suite to benchmark your genome editing strategy against the right decision-makers\n\n\n64% in vivo & 36% ex vivo agenda to fit your route of delivery\n\n\n2 brand-new workshops\n\nView the full program here to see the 18+ speaker faculty and full session details: https://ter.li/sda9n7qy
URL:https://www.pharmajournalist.com/event/7th-genome-editing-therapeutics-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260929
DTEND;VALUE=DATE:20261002
DTSTAMP:20260613T205947
CREATED:20260423T154336Z
LAST-MODIFIED:20260427T150843Z
UID:43381-1790640000-1790899199@www.pharmajournalist.com
SUMMARY:10th IPF Summit
DESCRIPTION:10th Anniversary Edition of the IPF Summit – \nSeptember 29 – October 1\, 2026 | Boston\, MA \nFor a decade\, the IPF Summit has been the go-to\, discussion-led forum uniting stakeholders across the pulmonary fibrosis ecosystem. In its 10th anniversary year\, the stakes\, and the opportunity\, have never been higher. \nFollowing a wave of positive Phase III readouts from leading companies including Bristol Myers Squibb\, United Therapeutics\, and Boehringer Ingelheim\, the field has entered a new era of momentum. But with this progress comes increasing complexity. As standards of care evolve and more therapies emerge\, the question is no longer can we develop treatments\, but how to do so smarter\, faster\, and with meaningful differentiation. \nThe 10th IPF Summit is the only end-to-end\, industry-led meeting designed to tackle this challenge head-on. \nBringing together 150+ experts across discovery\, translational science\, and clinical development\, from organizations including Bristol Myers Squibb\, United Therapeutics\, Boehringer Ingelheim\, Pfizer\, Novartis\, AbbVie\, PureTech Health\, Insilico Medicine\, and many more\, the summit offers a uniquely integrated view of the scientific\, clinical\, and strategic decisions shaping the next decade of IPF innovation. \nAcross dedicated content tracks\, dive into emerging biology and novel targets to unlock new therapeutic avenues\, biomarker-driven and translational strategies to generate clearer signals earlier and next-generation clinical trial design and combination approaches to succeed in an increasingly competitive landscape \nNew for 2026 includes a dedicated ILD & PPF Focus Day\, designed to unpack the complexity of fibrotic lung diseases beyond IPF\, alongside an investor panel offering insight into building conviction and demonstrating differentiated value in an evolving funding environment.\nWith 8+ hours of networking in an intentionally intimate setting\, the summit is built for honest\, high-value discussions\, giving you direct access to the people shaping the future of pulmonary fibrosis drug development. \nWhether you’re advancing early discovery\, translating assets into the clinic\, or positioning therapies in a crowded market\, this is where the field aligns on what success now looks like\, and how to achieve it. \nFind out more about the 10th Anniversary Edition of the IPF Summit: https://ter.li/5ny4yhvk
URL:https://www.pharmajournalist.com/event/10th-ipf-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261005
DTEND;VALUE=DATE:20261009
DTSTAMP:20260613T205947
CREATED:20260528T110955Z
LAST-MODIFIED:20260528T110955Z
UID:43630-1791158400-1791503999@www.pharmajournalist.com
SUMMARY:16th World Clinical Biomarkers & Companion Diagnostics Summit
DESCRIPTION:Fueled by surging digital pathology partnerships\, improved MRD sensitivity and high-plex single‑cell and multi‑omic profiling to breakthroughs\, the precision medicine field is evolving rapidly. \nBuilding on this momentum\, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns to Boston this fall\, uniting 850+ senior stakeholders in the common goal of advancing timely\, accessible and affordable precision medicine to patients in need. \nBe the first to access our new event program: https://ter.li/5c0adwgh \nJoin industry-leading peers from biopharma\, diagnostics\, testing labs\, and regulatory bodies\, to unpack fit-for-purpose CDx strategies\, spark new co-development partnerships\, discover cutting-edge genomic sequencing\, pathology\, multi-omic\, single cell and multimodal innovations. \nThis year’s agenda will expand to five dedicated tracks of content to ensure your entire team leave equipped with the tools and insights to tackle the specific challenges facing them at their stage of development. \n\nBiomarker Discovery & Translation\nClinical & CDx Development\nRx-Dx Commercialization & Adoption\nDigital Pathology & Spatial Biomarkers (BRAND-NEW)\nMultimodal & AI‑Enabled Endpoints (BRAND-NEW)\n\nGrasp the opportunity to attend the industry’s leading touchpoint for drug-diagnostic co-development advancement. \nTogether let’s translate promising precision medicine into scalable\, equitable drug-diagnostic therapies for patients across oncology\, neurological\, autoimmune\, rare and chronic diseases. \nSign up today: https://ter.li/0jb66uvu \nRegistration is FREE* for drug developers and researchers.  \n*Subject to terms and conditions visit the website to learn more.
URL:https://www.pharmajournalist.com/event/16th-world-clinical-biomarkers-companion-diagnostics-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261012
DTEND;VALUE=DATE:20261016
DTSTAMP:20260613T205947
CREATED:20260512T103447Z
LAST-MODIFIED:20260512T103447Z
UID:43484-1791763200-1792108799@www.pharmajournalist.com
SUMMARY:17th World ADC San Diego
DESCRIPTION:Returning as the largest and definitive ADC congress\, the 17th World ADC San Diego is THE one-stop bioconjugate shop\, bringing together the global ADC community for an unparalleled amalgamation of case studies\, development trends and networking opportunities to forge ADC innovation into differentiated\, early-line patient outcomes. \nWith 7 streams of end-to-end ADC content across Discovery Chemistry\, Discovery Biology\, Preclinical\, Translational Medicine\, Clinical Lessons\, Process & Analytical Development\, and Manufacturing & Supply\, all ADC innovation will be in the spotlight for an unmissable week of data and insights to de-risk future ADC development and push ADCs into earlier line oncology treatments. \nUniting 1\,300 industry senior enthusiasts from biopharma\, innovative start-ups\, leading service providers and academic\, physician and regulator KOLs\, World ADC San Diego is the place to discuss\, debate and advance the future of ADC development. \nFeaturing 170+ senior presenters\, a snapshot of the 2026 speaker faculty includes: \n\nSuzanne Edavettal\, Vice President\, Research & Head\, Protein Therapeutics\, Amgen\nVinod Bulusu\, Executive Director\, Product Stewardship Lead\, AstraZeneca\nGiorgia Vicentini\, Vice President\, Global Program Lead\, Oncology\, Bristol Myers Squibb\nRonald Fleming\, Executive Director\, Clinical Development\, Daiichi Sankyo\nGail Lewis\, Distinguished Scientist\, Discovery Oncology\, Genentech\nMin Hu\, Senior Vice President\, Discovery\, Innovent Biologics\nBob Lutz\, Chief Scientific Officer\, Iksuda Therapeutics\nJeffrey Settleman\, Chief Scientific Officer\, Oncology R&D\, Pfizer\nDominik Schumacher\, Chief Executive Officer\, Tubulis\nRita Nanda\, Associate Professor\, Medicine & Director\, Breast Oncology\, Section of Hematology/Oncology\, University of Chicago\n\nView the full list of speaking companies: https://ter.li/xsz013cs \nIf you want to stay competitive in the field\, you cannot miss World ADC San Diego to de-risk future ADC development and push ADCs to earlier-line oncology treatments.
URL:https://www.pharmajournalist.com/event/17th-world-adc-san-diego/
LOCATION:Town & Country San Diego\, 500 Hotel Circle\, North San Diego\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261026
DTEND;VALUE=DATE:20261030
DTSTAMP:20260613T205947
CREATED:20260609T083754Z
LAST-MODIFIED:20260609T083754Z
UID:43704-1792972800-1793318399@www.pharmajournalist.com
SUMMARY:9th TPD & Induced Proximity Summit
DESCRIPTION:After a decade of innovation\, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026\, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already\, the headwinds are reversing with $15B worth of upfront deals involving TPD candidates and companies in 2026 alone. \nHowever\, following the risk-averse funding environment of 2025\, continued positive clinical data is key to regaining investor confidence and pharma interest. That’s why the 9th TPD & Induced Proximity Summit is returning as the globe’s definitive forum to help you gain that ever-important clinical validation. As the world’s largest and most comprehensive TPD conference featuring the latest data from early discovery to clinical development\, it is designed to help you discover the best novel targets\, optimize your degrader profile\, and accelerate your pipelines to the clinic and beyond. \nView the full event guide.
URL:https://www.pharmajournalist.com/event/9th-tpd-induced-proximity-summit/
LOCATION:The Omni Boston Hotel at the Seaport\, 450 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR